ChinaBio® Today

Time 2021-09-15 16:22:43

Web Name: ChinaBio® Today

WebSite: http://www.chinabiotoday.com

ID:194027

Keywords:

ChinaBio,Today,

Description:

ChinaBio Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.Learn more Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!See preview Welcome to ChinaBio Today!As a guest to ChinaBio Today, you have access to summaries of over 3000 articles. You can use the Searchfunction to find what you're looking for, or you can browse summaries of our articles by Category(see left sidebar). You can also register for our Free Email Newsletteror Subscribe to have full access to all 3000 articles.Subscribe Alebund Pharma, a Shanghai company focused on renal diseases, closed a $54.5 million Series B+ financing round. Four months ago, the company completed a$60 millionB round. Alebund will use the proceeds to advance its clinical programs, build a manufacturing facility, research its pre-clinical assets and hire additional staff. Its lead program is a treatment for hyperphosphatemia, currently in a Phase II clinical trial. The B+ round was led by 3H Health Investment, Loyal Valley Capital and Morningside Ventures. More details.... Share this with colleagues: Harbour BioMed was approved to start China trials of its next-gen CLTA-4 candidate in combination with its PD-1 for two new indications: hepatocellular carcinoma and neuroendocrine tumor/neuroendocrine carcinoma. HBM believes HBM4003, a fully human anti-CTLA-4 mAb, has the potential to improve efficacy while reducing toxicity as a monotherapy and combo-therapy. Earlier this year, the CLTA-4/PD-1 combination started China trials for NSCLC. Harbour is headquartered in Cambridge, MA, with discovery operations in Rotterdam and development labs in Suzhou. More details....Stock Symbol:(HK: 02142) Share this with colleagues: Shanghai Everest Medicines announced a $500 million two-part deal with Providence Therapeutics of Calvery, Canada for mRNA products. Initially, Everest will acquire China-Asia rights to Providence's mRNA clinical stage COVID-19 vaccine for $50 million upfront and $100 million in profit sharing. The two companies will also enter a 50/50 global collaboration for twoadditional Providence mRNA prophylactic or therapeutic products, also with a $50 million upfront payment and up to $300 million in sales milestones (which will be paid in Everest stock). More details....Stock Symbol:(HK 1952) Share this with colleagues: Nanjing Legend Biotech has started a US Phase 1 trial of its autologous CD4 CAR-T therapy for lymphoma. The trial will enroll adult patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) or cutaneous T-cell lymphoma (CTCL). LB1901 targets CD4, a surface membrane glycoprotein expressed in most TCL subtypes. Legend's lead candidate, cilta-cel, is a BCMA-targeted CAR-T for multiple myeloma that is under review for marketing approval in China, the US and EU. Legend partnered cilta-cel with Janssen Pharma. More details....Stock Symbol:(NSDQ: LEGN) Share this with colleagues: France's Sanofi will acquireKadmon, a New York city pharma with a China JV and a newly approved graft-versus-host drug, in a $1.9 billion deal;FrontageShanghai, a division of US-China CRO Frontage Holdings, acquired a 70% stake in Wuhan Heyan Biomedical Technology, a discovery CRO;Bio-Thera Solutions out-licensed US, EU and Canadian commercial rights for its Avastin biosimilar to Sandoz;Huadong Medicine entered a partnership with Insilico Medicine, a Hong Kong AI drug discovery company, to develop small-molecule oncology candidates;Covid-19 PandemicBrii Biosciences ofBeijingcommitted an additional$100 millionfor global regulatory filings and commercialization of its SARS-CoV-2 combination therapy;Chengdu Clover Biopharma received a permit to manufacture its S-Trimer COVID-19 vaccine candidate at its Changxing facility;Sinovac Biotech said a third dose of its SARS-CoV-2 vaccine improved the protection of CoronaVac by 60%, including protection from the Delta variant;Trials and ApprovalsJW Therapeutics,a Shanghai CAR-T company, was approved to launch its anti-CD-19 CAR-T to treat large B-cell lymphoma inChina.Stock Symbols: (NSDQ: KDMN) (SHA: 688177) (SHZ: 000963) (NSDQ: SVA) (HK: 2126)

TAGS:ChinaBio Today 

<<< Thank you for your visit >>>

Hot Websites